Cargando…
Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients
Corona Virus Disease 2019 (COVID-19) has affected over 8 million people worldwide. We underscore the potential benefits of conducting a randomized open-label unblinded clinical trial to evaluate the role of ursodeoxycholic acid (UDCA) in the treatment of COVID-19. Some COVID-19 patients are characte...
Autores principales: | Subramanian, Subbaya, Iles, Tinen, Ikramuddin, Sayeed, Steer, Clifford J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350268/ https://www.ncbi.nlm.nih.gov/pubmed/32575350 http://dx.doi.org/10.3390/vaccines8020320 |
Ejemplares similares
-
HIV vaccines beyond COVID‐19: merits of trust
por: Kublin, James G
Publicado: (2021) -
Merits and Pitfalls of Social Media as a Platform for Recruitment of Study Participants
por: Oudat, Qutaibah, et al.
Publicado: (2023) -
Special Issue: MicroRNA Regulation in Health and Disease
por: Subramanian, Subbaya, et al.
Publicado: (2019) -
Host–MicroRNA–Microbiota Interactions in Colorectal Cancer
por: Yuan, Ce, et al.
Publicado: (2019) -
How Japan managed to curb the pandemic early on: Lessons learned from the first eight months of COVID-19
por: Sayeed, Urme Binte, et al.
Publicado: (2020)